By Marie Rosenthal
In a unanimous decision, the Advisory Committee on Immunization Practices (ACIP) voted to recommend the Moderna COVID-19 vaccine (Spikevax) two-dose primary series for people 18 years of age and older, which the FDA approved on Jan. 31.
All other COVID-19 ACIP recommendations that address the use of COVID-19 vaccines under an emergency use authorization (EUA), such as booster or third doses for immunocompromised individuals, remain in effect.
The FDA granted full approval for